0

Aurinia Pharmaceuticals (AUPH) Tumbles After Major Setback

On Monday, Aurinia Pharmaceuticals (NASDAQ:AUPH) announced positive phase 2b results in patients with lupus nephritis. The company was testing its drug Voclosporin in combination with standard of care — Roche (OTCMKTS:RHHBY) drug known as CellCept. While the trial results were positive the… Continue Reading

0

Cytrx Shares Fall 66% After Phase 3 Sarcoma Trial Failure

In pre-market trading, on July 12 2016, shares of Cytrx Corporation (NASDAQ:CYTR) fell by 66% as the company had announced that its Phase 3 trial treating sarcoma patients failed to meet the primary endpoint of the study. The phase 3 trial… Continue Reading

0

Juno Therapeutics (JUNO) Tanks 30% Pre-Market After FDA Halts Cancer Trial

On July 8, 2016 in pre-market trading, shares of Juno Therapeutics (NASDAQ:JUNO) are down 30% after the company announced that one its leukemia cancer trials has been halted due to two patient deaths. This pivotal trial, ‘ROCKET,’ was one that… Continue Reading

0

Inovio (INO) Receives Authorization For First Human Zika Virus Trial

On Monday Inovio Pharmaceuticals (NASDAQ:INO) and subsidiary Gene One life sciences received authorization to begin the first ever trial in humans for the Zika Virus. This trial will be a phase 1 clinical trial utilizing Inovio’s Zika vaccine candidate, known… Continue Reading

0

Revance Fails Phase 3 Trial; Shares Down 24% In After-Hours

Shares of Revance Therapeutics (NASDAQ:RVNC) fell by 24% in after-hours trade after the company reported that its phase 3 clinical trial failed to meet the primary endpoint. The phase 3 trial was using the company’s drug RT001 to treat patients… Continue Reading

0

Sophiris Bio Closes Up 69% After Successful Phase 2 Prostate Cancer Results

Shares of Sophiris Bio (NASDAQ:SPHS) closed the day up 69% after the company announced that it had received positive phase 2a results in patients with prostate cancer. The phase 2a trial was a proof of concept study to see if… Continue Reading